Products
Prafnosbart Biosimilar Monoclonal Antibody (ALK2) for Research
Cat No.: GMP-Bios-INN-1346
Anti-ACVR1 therapeutic antibody (Pre-made Prafnosbart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Prafnosbart (development code DS-6016A) is a humanized monoclonal antibody targeting ACVR1 (ALK2). It is developed by Daiichi Sankyo for Fibrodysplasia ossificans prograssiva in Phase I development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1346-1mg | 1mg | 3090 |
| GMP-Bios-INN-1346-10mg | 10mg | |
| GMP-Bios-INN-1346-100mg | 100mg | |
| GMP-Bios-INN-1346-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Prafnosbart biosimilar, Whole mAb, Anti-ACVR1 Antibody: Anti-ACVR1/ALK-2/Activin receptor type-1/Activin receptor type I (ACTR-I) therapeutic antibody |
| INN Name | Prafnosbart |
| Target | ACVR1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Daiichi Sankyo |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Fibrodysplasia ossificans prograssiva |
| Production | na |
| Development Tech | na |
